LG Life Sciences sign a deal to introduce Demomed's Gastric Retention

Published: 2004-08-25 06:59:00

Updated: 2004-08-25 06:59:00

LG Life Sciences said that it signed an exclusive license agreement with the US-based Depomed Inc. to distribute Metformin Gastric Retention (GR) in Korea.

Depomed filed an US NDA for Metformin GR for use in the treatment of diabetes in April after successful completion of Phase III trial. Th...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK